Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38294179/
1 TECHNICAL EFFICACY: Stage 4.
Median surface/average anisotropy of the peritumoral region, measured after 2 and 4 cycles of neoadjuvant systemic treatment, increased in patients with pathologic CRs and decreased in patients with nonpathologic CRs.
Abemaciclib as Adjuvant Treatment for High-Risk Early Breast Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38114413/
The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results...
With a median follow-up of 15.5 months, abemaciclib plus endocrine therapy demonstrated a statistically significant improvement in invasive disease-free survival versus endocrine therapy alone.
-
Albert Dekker1yrwe need more data on patient selection; I have talk to 5 different KOL about Verzenio in BRCA positive population and got 5 different answers
First-Line CDK4/6 Inhibitor-Based Combinations for HR+/HER2- Advanced Breast Cancer: a Bayesian Network Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/38102891/
Ribociclib+fulvestrant probably represents the best option in a first-line setting. When combined with NSAI, dalpiciclib likely showed the best efficacy but the worst safety. Abemaciclib+NSAI and ribociclib+NSAI could also be...
Considering OS, the top 3 ranked treatments were ribociclib plus fulvestrant, abemaciclib plus NSAI, and ribociclib plus NSAI.
-
Albert Dekker1yrmany patients especially smaller petite women have the real issue with Verzenio and almost all of them need to be dose reduced at least once
!["Not Even My Husband Knows That I Have This [Breast Cancer]": Survivors' Experiences in Accessing, Navigating and Coping With Treatment](https://static-content-prd.skipta.com/public/skipta/skipta-post/2024-01/file7NR9uj "\"Not Even My Husband Knows That I Have This [Breast Cancer]\": Survivors' Experiences in Accessing, Navigating and Coping With Treatment")
"Not Even My Husband Knows That I Have This [Breast Cancer]": Survivors' Experiences in Accessing, Navigating and Coping With Treatment
Source : https://pubmed.ncbi.nlm.nih.gov/38236480/
The integration of innovative technologies for venous access and other treatment needs of BC is crucial and will improve survivorship. Non-disclosure of BC diagnosis is personal and complicated; hence, BC...
Participants described how they concealed their breast cancer diagnosis from family and significant others while accessing and navigating their cancer treatment.
-
Albert Dekker1yrThis is an important issue; I have a few patients who want to hide their Dx for whatever reasons. A couple times I had to go to CMF to ensure Show More
Phase II DORA Study of Olaparib With or Without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38236575/
PFS was longer than expected with both regimens. A patient subset with wild-type BRCA platinum-sensitive aTNBC had durable disease control with chemotherapy-free maintenance.
At 9.8 months of median follow-up, median PFS rates from randomization were 4.0 months with olaparib and 6.1 months with combination treatment, both of which were significantly longer than the historical control treatment.
-
Albert Dekker1yrit is great but presence of other mutations and correlation with and against HRD is not addressed here.